The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study

BMC Veterinary Research

Jolle Kirpensteijn³  Marja J L Kik²  Bart E Sjollema¹  Astrid C S Witkamp³  Annika N Haagsman³ 

[1] Animal Medical Centre Amsterdam (AMCA), Isolatorweg 45, 1014AS Amsterdam, The Netherlands;Department of Pathobiology, Pathology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan1, 3584CL Utrecht, The Netherlands;Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Postbus 80154, 3508, TD Utrecht, The Netherlands

关键词: Injection;    Intralesional;    Surgery;    PNST;    rhIL2;    Dog;    Sarcoma;   

Others  :  1119483
DOI  :  10.1186/1746-6148-9-155

 received in 2013-03-25, accepted in 2013-07-31,  发布年份 2013

【 摘 要 】

Background

The objective of this study was to evaluate the effect on outcomes of intraoperative recombinant human interleukin-2 injection after surgical resection of peripheral nerve sheath tumours. In this double-blind trial, 40 patients due to undergo surgical excision (<5 mm margins) of presumed peripheral nerve sheath tumours were randomized to receive intraoperative injection of interleukin-2 or placebo into the wound bed.

Results

There were no significant differences in any variable investigated or in median survival between the two groups. The median recurrence free interval was 874 days (range 48–2141 days), The recurrence-free interval and overall survival time were significantly longer in dogs that undergone the primary surgery by a specialist-certified surgeon compared to a referring veterinarian regardless of whether additional adjunct therapy was given.

Conclusion

Overall, marginal excision of peripheral nerve sheath tumours in dogs resulted in a long survival time, but adjuvant treatment with recombinant human interleukin-2 (rhIL-2) did not provide a survival advantage.

【 授权许可】

   
2013 Haagsman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Nimwegen S, Kirpensteijn J: Specific disorders. In Veterinary surgery: small animal. 1st edition. Edited by Tobias KM, Johnston SA. USA: Saunders Elsevier; 2012:1316.
• [2]Mauldin GN: Soft tissue sarcomas. Vet Clin Small Anim Pract 1997, 27(1):139-148.
• [3]Hendrick MJ, Mahaffey EA, Moore FM, et al.: World Health Organization International histological classification of tumors of domestic animals. Second Series, Volume II. Washington, DC: Armed Forces Institute of Pathology in cooperation with the Americam Registry of Pathology and the World Health Organization Collaborating Center for Worlwide Reference on Comparative Oncology; 1998:16. [Histological classification of mesenchymal tumors of the skin and soft tissues of domestic animals]
• [4]Goldschmidt MH, Shofer FS: Melanoma. In Skin tumors of the dog and cat. 2nd edition. Oxford: Elsevier Books; 1999:131-141.
• [5]Kaldrymidou H, Leontides L, Koutinas AF, Saridomichelakis MN, Karayannopoulou M: Prevalence, distribution and factors associated with the presence and the potential for malignancy of cutaneous neoplasms in 174 dogs admitted to a clinic in northern Greece. J Vet Med A Physiol Pathol Clin Med 2002, 49(2):87-91.
• [6]Pakhrin B, Kang MS, Bae IH, Parks MS, Jee H, You MH, Kim JH, Yoon BI, Choi YK, Kim DY: Retrospective study of canine cutaneous tumors in Korea. J Vet Sci 2007, 8(3):229-236.
• [7]Ehrhart N: Soft-tissue sarcomas in dogs: a review. J Am Anim Hosp Assoc 2005, 41:241-246.
• [8]Brehm DM, Vite CH, Steinberg HS, Haviland J, van Winkle T: A retrospective evaluation of 51 cases of peripheral nerve sheath tumors in the dog. J Am Anim Hosp Assoc 1995, 31(4):349-359.
• [9]Harcourt-Brown TR, Granger N, Smith PM, Hughes K, Jeffery ND: Use of a lateral surgical approach to the femoral nerve in the management of two primary femoral nerve sheath tumours. Vet Comp Orthop Traumatol 2009, 22(3):229-23.
• [10]Gaitero L, Anor S, Fondevila D, Pumarola M: Canine cutaneous spindle cell tumours with features of peripheral nerve sheath tumours: a histopathological and immunohistochemical study. J Comparable Pathol 2008, 139(1):16-23.
• [11]Liptak JM, Forrest LJ, et al.: Soft tissue sarcomas. In Withrow & MacEwen’s: small animal clinical oncology. 4th edition. Edited by Withrow SJ, Vail DM. St Louis, USA: Saunders Elsevier; 2007:211-234. 425–454
• [12]McSporran KD: Histologic grade predicts recurrence for marginally excised canine subcutaneous soft tissue sarcoma. Vet Pathol 2009, 46(5):928-933.
• [13]Ettinger SN: Principles of treatment for soft-tissue sarcomas in the dog. Clin Tech Small Anim Pract 2003, 18(2):118-122.
• [14]Selting KA, Powers BE, Thomson LJ, Mittleman E, Tyler JW, Lafferty MH, Withrow SJ: Outcome of dogs with high-grade soft-tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996–2004). J Am Vet Med Assoc 2005, 227(9):1442-1448.
• [15]Rassnick KM: Medical management of soft-tissue sarcomas. Vet Clin North Am Small Anim Pract 2003, 33(3):517-531.
• [16]Seung SK, Curti B, Crittenden M, Urba W: Radiation and immunotherapy: renewed allies in the war on cancer. Oncoimmunology 2012, 1(9):1645-1647.
• [17]Fukushima K, Dejima K, Koike S, Tei G, Asano J, Ueda M, Hyuga M, Oshima W: A case of angiosarcoma of the nasal cavity successfully treated with recombinant interleukin-2. Otolaryngol Head Neck Surg 2006, 134(5):886-887.
• [18]Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988, 208(2):121-135.
• [19]Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM: Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 2008, 57(7):1091-1104.
• [20]Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Kratev Z, Moiseeva EV, Stewart RJE, Ziekman PGPM, Koten JW: Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008, 57(7):931-950.
• [21]Toma S, Melioli G, Palumbo R, Rosso R: Recombinant interleukin-2 and interferon-alpha-2a in pretreated advanced soft-tissue sarcomas. Int J Oncol 1993, 2(6):997-1001.
• [22]Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft tissue sarcomas. Br J Cancer 2003, 89(9):1620-1626.
• [23]Shaker MA, Younes HM: Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci 2009, 98(7):2268-2298.
• [24]Maas RA, Dullens HF, De Jong WH, Den Otter W: Immunotherapy of mice with large burden of disseminated lymphoma with low dose interleukin-2. Cancer Res 1989, 49(24 Pt 1):7037-7040.
• [25]Krastev Z, Koltschakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W: Locoregional IL-2 low dose applications for gastro-intestinal tumors. World J Gastroenterol 2005, 11(35):5525-5529.
• [26]Jacobs JJ, Sparendam D, Den Otter W: Local interleukin 2 therapy is most effective against cancer when injected intratumourally. Cancer Immunol Immunother 2005, 54(7):647-654.
• [27]Van Es RJ, Baselmans AH, Koten JW, Van Dijk JE, Koole R, Den Otter W: Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumor activity. Anticancer Res 2000, 20(6B):4163-4170.
• [28]Bernsen MR, Van Der Velden AW, Everse LA, Dullens HFJ, Den Otter W, Heintz PM: Interleukin-2: hope in cases of cisplatin-resistant tumours. Cancer Immunol Immunother 1998, 46(1):41-47.
• [29]Maas RA, Henk D, Van Weering J, Dullens HFJ, Den Otter W: Intratumoral low-dose interleukin-2 induces rejection of distant solid tumor. Cancer Immunol Immunother 1991, 33(6):389-394.
• [30]Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W: Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages. Immunobiology 1992, 186(3–4):214-229.
• [31]Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HF, Den Otter W: Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice. Immunobiology 1993, 188(3):281-292.
• [32]Bernsen MR, Tang JW, Everse LA, Koten JW, Den Otter WD: Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev 1999, 25(2):73-82.
• [33]Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT: Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors. Cancer Immunol Immunother 2003, 52(8):473-480.
• [34]Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R: Effective cancer therapy with a single injection. Cancer Immunol Immunother 1999, 48:419-420.
• [35]Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW, Den Otter W: Treatment of ocular squamous cell carcinoma in cattle with interleukin-2. Vet Res 2006, 159(20):668-672.
• [36]Spoormakers TJ, Klein WR, Jacobs JJ, Van Den Ingh TS, Koten JW, Den Otter W: Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 2003, 52(3):179-184.
• [37]Ziekman PGPM, Den Otter W, Tan JFV, Teske E, Kirpensteijn J, Koten J, Javobs JJL: Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs. Anticancer Res 2013, 33:161-166.
• [38]Radny P, Caroli UM, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620-1626.
• [39]Hill FW, Klein WR, Hoyer MJ, Rutten VP, Kock JW, Steerenberg PA, Ruitenberg EJ, Den Otter W: Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 1994, 41(1–2):19-29.
• [40]Dernell WS, Straw RC, Cooper MF, Powers BE, LaRue SM, Withrow SJ: Multilobular osteochondrosarcoma in 39 dogs: 1979–1993. J Am Hosp Assoc 1998, 34(1):11-18.
• [41]Kuntz CA, Dernell WS, Powers BE, Devitt C, Straw RC, Withrow SJ: Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986–1996). J Am Vet Med Assoc 1997, 211(9):1147-1151.
• [42]McKnight JA, Mauldin GN, McEntee MC, Meleo KA, Patnaik AK: Radiation treatment for incompletely resected soft-tissue sarcomas in dogs. J Am Vet Med Assoc 2000, 217(2):205-210.
• [43]Elmslie RE, Glawe P, Dow SW: Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. J Vet Intern Med 2008, 2(6):1373-1379.
• [44]Bacon NJ, Dernell WS, Ehrhart N, Powers BE, Withrow SJ: Evaluation of primary re-excision after recent inadequate resection of soft tissue sarcomas in dogs: 41 cases (1999–2004). J Am Vet Med Assoc 2007, 230(4):548-554.
• [45]Khanna C, Anderson PM, Hasz DE, Katsanis MD, Neville M, Klausner JS: Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Am Cancer Soc 1997, 79(April 1):1409-1421.
• [46]Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D: Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 1989, 195(11):1580-1583.
• [47]Havlicek M, Straw RS, Langova V, Dernell WS: Intra-operative cisplatin for the treatment of canine extremity soft tissue sarcomas. Vet Comp Oncol 2009, 7(2):122-129.
• [48]Lawrence J, Forrest L, Adams W, Vail D, Thamm D: Four-fraction radiation therapy for macroscopic soft tissue sarcomas in 16 dogs. J Am Anim Hosp Assoc 2008, 44(3):100-108.
• [49]Stefanello D, Morello E, Roccabianca P, Lussich S, Nassuato C, Martano M, Squassino C, Avallone G, Romussi S, Buracco P: Marginal excision of low-grade spindle cell sarcoma of canine extremities: 35 dogs (1996–2006). Vet Surg 2008, 37(5):461-465.
• [50]Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E: Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe. J S Afr Vet Assoc 2005, 76(2):59-62.